![]() |
市場調查報告書
商品編碼
1715190
2031年亞太地區液體切片採血管市場預測-區域分析-依產品、材料、應用及最終用戶Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Forecast to 2031 - Regional Analysis - by Product, Material, Application, and End User |
2023年亞太地區液體切片採血管市場價值為287.4623億美元,預計2031年將達到1161.6956億美元;預計2023年至2031年的複合年成長率為19.1%。
液體活體組織切片在癌症監測中的應用推動了亞太地區液體活體組織切片採血管市場的發展
人們越來越關注採用液體活體組織切片程序來監測癌症生長、檢測基因突變、識別復發跡像以及預測對免疫療法的敏感性。早期發現癌症可帶來更好的治療效果;例如,早期發現的癌症患者的緩解率和存活率比晚期或惡性癌症患者更高。然而,在症狀不明顯的早期階段進行一系列放射學檢測或侵入性癌症監測程序來檢測癌症是不切實際的。液體活體組織切片使得透過常規抽血或尿液分析進行定期癌症篩檢成為可能。它可以識別高度特異性和循環標記物,以用於早期癌症檢測。
液體活體組織切片程序也用於癌症患者的治療後監測。治療後癌細胞仍可能在體內持續存在,但其水平低於影像學研究的解析度和檢測水平;這種狀況被稱為微小殘留疾病。這種疾病被認為是癌症緩解的主要原因。與癌症篩檢和早期檢測類似,液體活體組織切片的臨床應用受到目前測試的敏感性和特異性的限制。然而,由於這種敏感性限制,液體活體組織切片技術可用於檢測實體腫瘤而非血癌的微小殘留疾病。借助液體活體組織切片,醫療保健專業人員可以監測癌症復發的情況,然後透過正確的診斷儘早治療。
最初對特定酪胺酸激酶抑制劑(包括吉非替尼、厄洛替尼、克唑替尼和色瑞替尼)敏感的腫瘤經常發生變異並對這些藥物產生抗藥性。液體切片檢查可以檢測腫瘤狀態的變化,並幫助醫生修改治療策略,以避免患者體內對任何藥物產生抗藥性。因此,液體活體組織切片可以早期發現癌症並幫助醫療保健專業人員確定確切的治療方案。此外,它還有助於監測治療過程以及治療後患者的狀況。因此,人們越來越關注液體活體組織切片在癌症患者監測中的應用,這可能會在預測期內對液體活體組織切片程序的採血管產生大量需求。
亞太地區液體切片採血管市場概況
亞太地區液體切片採血管市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。由於該地區癌症患者數量激增,對採血管的需求也增加。此外,政府加強醫療保健基礎設施和支持研究的舉措預計將在預測期內為市場成長創造重大機會。在中國,政府對醫療基礎設施的大量投資以及對提供強化醫療服務的重視使液體活體組織切片採血管市場受益。癌症病例的增加也促進了市場的成長,因為這表明對液體活體組織切片等複雜診斷工具的需求增加。 2017 年 5 月,Streck 與中國綜合分子診斷分銷商 GenomePrecision Technology 簽署了分銷協議,分銷其細胞穩定、分子、尿液分析和流式細胞術產品。無細胞 DNA BCT 和無細胞 RNA BCT(皆可穩定有核血細胞)以及無細胞 DNA 尿液保存劑皆屬於 Streck 的細胞穩定產品。這表明中國的主要市場參與者專注於加強其產品管道,以抓住該國市場的成長機會。此外,Vazyme Biotech 和 CNWTC 等生技公司也提供 cfDNA 管、液體切片試劑盒、藥物研發、分子研究等產品。
亞太地區液體切片採血管市場收入及預測(2031年)(百萬美元)
亞太地區液體切片採血管市場細分
亞太地區液體切片採血管市場依產品、材料、應用、最終用戶、國家分類。
根據產品,亞太地區液體切片採集血管市場分為 ccfDNA/cfDNA 管、cfRNA 管、CTC 管、gDNA 管、細胞內 RNA 管等。 2023 年,ccfDNA/cfDNA 管細分市場佔據亞太地區液體活體組織切片採血管市場最大佔有率。
從材質來看,亞太地區液體切片採集血管市場分為塑膠和玻璃。 2023 年,塑膠部分在亞太地區液體活體組織切片採血管市場中佔有較大佔有率。
根據應用,亞太地區液體切片採集血管市場分為體外診斷(IVD)和研究。 2023 年,體外診斷 (IVD) 領域在亞太地區液體活體組織切片採血管市場中佔據較大佔有率。
就最終用戶而言,亞太地區液體切片採血管市場分為基因診斷實驗室、研發中心、傳統診斷中心等。 2023 年,基因診斷實驗室部門佔據亞太地區液體活體組織切片採血管市場的最大佔有率。
根據國家/地區,亞太地區液體活體組織切片採血管市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。 2023 年,中國佔據亞太地區液體切片採血管市場最大佔有率。
Biocept公司;精確科學公司; F.霍夫曼-羅氏有限公司; Greiner Bio-One International GmbH; MagBio Genomics 公司; Norgen Biotek 公司; QIAGEN NV;斯特雷克公司;和 Zymo Research Corporation 是亞太地區液體活體組織切片採血管市場領先的公司之一。
The Asia Pacific blood collection tubes for liquid biopsy market was valued at US$ 28,746.23 million in 2023 and is expected to reach US$ 1,16,169.56 million by 2031; it is estimated to register a CAGR of 19.1% from 2023 to 2031.
Use of Liquid Biopsy in Cancer Monitoring Boosts Asia Pacific Blood Collection Tubes for Liquid Biopsy Market
There is a growing focus on employing liquid biopsy procedures for monitoring cancer growth, detecting genetic mutations, identifying signs of relapse, and predicting sensitivity to immunotherapy. The early detection of cancer results in better outcomes; for example, patients with early detection show higher remission and survival rates than those with late-stage or malignant cancer. However, it is impractical to perform serial radiological testing or invasive procedures for cancer surveillance to detect cancer in the early stages when symptoms are not evident. Liquid biopsy unlocks the possibility of periodic cancer screening through routine blood draws or urinalyses. It can identify highly specific and circulating markers for early cancer detection.
Liquid biopsy procedures are also employed for post-treatment monitoring of cancer patients. Cancer cells may persist in the body after treatment at levels below the resolution and detection levels of imaging studies; the condition is termed a minimal residual disease. This disease is considered a principal cause of cancer remission. Similar to that in cancer screening and early detection, the clinical application of liquid biopsy is limited by the sensitivity and specificity of current tests. However, due to this sensitivity limitation, liquid biopsy techniques can be used for detecting minimal residual disease for solid tumors than blood cancers. With the help of liquid biopsy, the healthcare professional can monitor the case of reoccurrence of cancer, which can then be treated early with the help of proper diagnosis.
Tumors that are initially susceptible to specific tyrosine kinase inhibitors, including gefitinib, erlotinib, crizotinib, and ceritinib, often mutate and develop resistance to these drugs. Liquid biopsy detects the changes in the tumor status and helps doctors modify the treatment strategies to avoid the development of resistance to any medication in the patient's body. Thus, liquid biopsy allows the early detection of cancer and helps healthcare professionals determine the exact course of action for treatment. In addition, it helps monitor treatments and the condition of the patient after the treatment. Thus, there is an increase in focus on the use of liquid biopsy in the monitoring of cancer patients, which is likely to create a significant demand for blood collection tubes for liquid biopsy procedures during the forecast period.
Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Overview
The Asia Pacific blood collection tube for liquid biopsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. The demand for blood collection tubes is increasing due to an upsurge in the number of cancer patients in the region. Moreover, government initiatives to enhance healthcare infrastructure and support research studies are expected to create significant opportunities for market growth during the forecast period. In China, significant government investments in healthcare infrastructure and emphasis on providing enhanced medical services benefit the blood collection tubes for liquid biopsy market. The increasing number of cancer cases is also contributing to the market growth, as it indicates the elevated need for sophisticated diagnostic tools such as liquid biopsies. In May 2017, Streck signed a distribution agreement with GenomePrecision Technology, an integrated molecular diagnostics distributor in China, for its cell stabilization, molecular, urinalysis, and flow cytometry products. Cell-Free DNA BCT and Cell-Free RNA BCT (both stabilize nucleated blood cells), and Cell-Free DNA Urine Preserve are among Streck's cell stabilization products. This signifies that key market players in China focus on enhancing their product access to grab growth opportunities in the market in this country. Further, biotechnology companies such as Vazyme Biotech and CNWTC offer products for cfDNA tubes, liquid biopsy kits, drug discovery, molecular research, and more.
Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Revenue and Forecast to 2031 (US$ Million)
Asia Pacific Blood Collection Tubes for Liquid Biopsy Market Segmentation
The Asia Pacific blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.
By product, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.
In terms of material, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.
By application, the Asia Pacific blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.
In terms of end user, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the Asia Pacific blood collection tubes for liquid biopsy market share in 2023.
Based on country, the Asia Pacific blood collection tubes for liquid biopsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China segment held the largest share of Asia Pacific blood collection tubes for liquid biopsy market in 2023.
Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the Asia Pacific blood collection tubes for liquid biopsy market.